Galway, 25th November 2022 –OmniSpirant Limited and EVerZom are delighted and honoured to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant in collaboration with our European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy, are already actively working on the project deliverables, and recently met in Galway, Ireland for the official kick-off meeting (see the picture below taken on the 28th October 2022). [Read more…]
Avectas, CCRM and OmniaBio Expand Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology
DUBLIN, Ireland and TORONTO, Canada, Nov. 29, 2022 — Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the development of cell therapies and associated technologies for clinical and commercial manufacture, have announced an expansion of their collaboration, to enable the development of gene-edited induced pluripotent stem cells (iPSCs) using Avectas’ non-viral cell engineering platform, SOLUPORE®. [Read more…]
Caribou Biosciences Granted FDA RMAT and Fast Track Designations for CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial
CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout
Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing COPD
Phase III Clinical Trial Stem Cell Company Aims to Fast Forward Regenerative Solutions to Dreaded Lung Disease
November 9, 2022, ELK CITY, Idaho — Therapeutic Solutions International (TSOI) announced the launching of a spin-off company, Breathe Biologics, Inc., to commercialize technologies in the area of COPD. [Read more…]
Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development
Rotterdam and Leiden, the Netherlands, November 23, 2022 – Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of novel second generation TCR-T therapies against solid tumors, and NecstGen B.V., The Netherlands Center for the Clinical Advancement of Stem Cells and Gene Therapy, today announced a partnership to advance Pan Cancer T’s innovative therapies into the clinic. Under the agreement, NecstGen will provide process and analytical development capabilities. [Read more…]
- 1
- 2
- 3
- …
- 74
- Next Page »
